Abstract:
BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes. METHODS:We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors between January 2016 and February 2018. RESULTS:The mean patient age was 63.9 years, and 72.5% (37/51) were male. Most (92.2%, 47/51) had received previous systemic treatment. The overall response rate was 21.6% (11/51). The response rate was significantly lower in patients with pleural or pericardial metastasis than in patients without pleural or pericardial metastasis (4.3% vs. 35.7%; P = 0.007). Patients with pleural or pericardial metastasis had a significantly higher rate of adverse events of any grade (91.3% vs. 50.0%; P = 0.002) and grade 3-5 adverse events (52.2% vs. 25.0%; P = 0.046). CONCLUSION:Pleural or pericardial metastasis is a significant factor affecting the efficacy and rate of adverse events in advanced NSCLC patients treated with PD-1/PD-L1 inhibitors. Clinicians should pay attention to the use of immune checkpoint inhibitors in lung cancer patients with pleural or pericardial metastasis.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JEdoi
10.1111/1759-7714.12877subject
Has Abstractpub_date
2018-11-01 00:00:00pages
1500-1508issue
11eissn
1759-7706issn
1759-7714journal_volume
9pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13728
更新日期:2021-01-06 00:00:00
abstract::Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13159
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13504
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13364
更新日期:2020-04-01 00:00:00
abstract::Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13471
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12097
更新日期:2014-07-01 00:00:00
abstract:BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13211
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13660
更新日期:2020-11-01 00:00:00
abstract::This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13036
更新日期:2019-05-01 00:00:00
abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12617
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12993
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13653
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...
journal_title:Thoracic cancer
pub_type: 临床试验,杂志文章
doi:10.1111/1759-7714.12966
更新日期:2019-02-01 00:00:00
abstract::The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/1759-7714.12613
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12336
更新日期:2016-04-26 00:00:00
abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12484
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12499
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13336
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:Eugenol, a natural compound available in Syzigium aromaticum (cloves), is exploited for various medicinal applications. Eugenol induces apoptosis and functions as an anti-cancer drug in several types of tumors. We investigated the tumor suppressive role and potential mechanisms of eugenol in human lung cance...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12508
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13388
更新日期:2020-06-01 00:00:00
abstract::Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13694
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13526
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13080
更新日期:2019-07-01 00:00:00
abstract::The role of Chlamydia pneumoniae in the cause of lung cancer is controversial. In this study, we investigated the association between C. pneumoniae immunoglobulin (Ig) G antibodies and risk of lung cancer among non-smoking women. C. pneumoniae IgG antibody levels were compared between 192 adult Chinese women who met t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2010.00021.x
更新日期:2010-09-01 00:00:00
abstract:BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12500
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12454
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12847
更新日期:2018-11-01 00:00:00
abstract::Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13466
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12442
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND: The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00152.x
更新日期:2013-05-01 00:00:00